» Articles » PMID: 20442201

Colitis Induced in Mice with Dextran Sulfate Sodium (DSS) is Mediated by the NLRP3 Inflammasome

Overview
Journal Gut
Specialty Gastroenterology
Date 2010 May 6
PMID 20442201
Citations 397
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The proinflammatory cytokines interleukin 1beta (IL-1beta) and IL-18 are central players in the pathogenesis of inflammatory bowel disease (IBD). In response to a variety of microbial components and crystalline substances, both cytokines are processed via the caspase-1-activating multiprotein complex, the NLRP3 inflammasome. Here, the role of the NLRP3 inflammasome in experimental colitis induced by dextran sodium sulfate (DSS) was examined.

Methods: IL-1beta production in response to DSS was studied in macrophages of wild-type, caspase-1(-/-), NLRP3(-/-), ASC(-/-), cathepsin B(-/-) or cathepsin L(-/-) mice. Colitis was induced in C57BL/6 and NLRP3(-/-) mice by oral DSS administration. A clinical disease activity score was evaluated daily. Histological colitis severity and expression of cytokines were determined in colonic tissue.

Results: Macrophages incubated with DSS in vitro secreted high levels of IL-1beta in a caspase-1-dependent manner. IL-1beta secretion was abrogated in macrophages lacking NLRP3, ASC or caspase-1, indicating that DSS activates caspase-1 via the NLRP3 inflammasome. Moreover, IL-1beta secretion was dependent on phagocytosis, lysosomal maturation, cathepsin B and L, and reactive oxygen species (ROS). After oral administration of DSS, NLRP3(-/-) mice developed a less severe colitis than wild-type mice and produced lower levels of proinflammatory cytokines in colonic tissue. Pharmacological inhibition of caspase-1 with pralnacasan achieved a level of mucosal protection comparable with NLRP3 deficiency.

Conclusions: The NLRP3 inflammasome was identified as a critical mechanism of intestinal inflammation in the DSS colitis model. The NLRP3 inflammasome may serve as a potential target for the development of novel therapeutics for patients with IBD.

Citing Articles

TXM-CB13 Improves the Intestinal Mucosal Barrier and Alleviates Colitis by Inhibiting the ROS/TXNIP/TRX/NLRP3 and TLR4/MyD88/NF-κB/NLRP3 Pathways.

Cao R, Zhou J, Liu J, Wang Y, Dai Y, Jiang Y Inflammation. 2025; .

PMID: 40085192 DOI: 10.1007/s10753-025-02282-9.


Immune-Mediated Bidirectional Causality Between Inflammatory Bowel Disease and Chronic Periodontitis: Evidence from Mendelian Randomization and Integrative Bioinformatics Analysis.

Feng Z, Chen Z, Wang X, Zhou M, Liu S Biomedicines. 2025; 13(2).

PMID: 40002889 PMC: 11853167. DOI: 10.3390/biomedicines13020476.


Odoribacter splanchnicus-derived extracellular vesicles alleviate inflammatory bowel disease by modulating gastrointestinal inflammation and intestinal barrier function via the NLRP3 inflammasome suppression.

Zhuang J, Zhuang Z, Chen B, Yang Y, Chen H, Guan G Mol Med. 2025; 31(1):56.

PMID: 39934686 PMC: 11816829. DOI: 10.1186/s10020-025-01063-2.


New applications of clioquinol in the treatment of inflammation disease by directly targeting arginine 335 of NLRP3.

Chen P, Wang Y, Tang H, Zhou C, Liu Z, Gao S J Pharm Anal. 2025; 15(1):101069.

PMID: 39902456 PMC: 11788862. DOI: 10.1016/j.jpha.2024.101069.


Decursinol angelate relieves inflammatory bowel disease by inhibiting the ROS/TXNIP/NLRP3 pathway and pyroptosis.

Wang Y, Wang J, Chen Y, Li X, Jiang Z Front Pharmacol. 2025; 15():1520040.

PMID: 39840084 PMC: 11747577. DOI: 10.3389/fphar.2024.1520040.